Active Biotech Initiates Phase-II Clinical Trial For Prostate Cancer Drug

Active Biotech has announced that patient enrollment to the phase II clinical trial for TASQ, a novel compound for the treatment of prostate cancer, is completed. The company has enrolled over 200 patients for the study.

The study is a 2:1 randomized, placebo-controlled, double-blind phase II study of 1mg/day TASQ versus placebo. The study encompasses symptom free patients with metastatic, hormone-resistant, prostate cancer.

The primary endpoint of the study is to measure the proportion of patients that do not display disease progression after six months of TASQ therapy, as compared with placebo. Secondary clinical endpoints of importance for this group of patients include time to clinical progression, safety and to measure changes in PSA (Prostate Specific Antigen) blood levels.

Results from this study are expected by the end of 2009 or beginning of 2010.